An increased expression of immature glycan (Tn antigen) on mucin is reported in patients with active UC.43–45 Thus, our data suggest that B3GALT5-targeted therapy in a subset of patients with IBD may alleviate disease symptoms. This evidence concerns the gene B3GALT5 and inflammatory bowel disease.